Key Points
- Director Christopher Causey sold 1,000 United Therapeutics shares on January 2 at an average price of $500.01 for $500,010, leaving him with 4,190 shares (a 19.27% reduction) valued at about $2.095M.
- United Therapeutics reported quarterly EPS of $7.16 (beating estimates of $6.89) with $799.5M revenue (slightly below expectations), and strong profitability metrics including a 40.65% net margin and 18.83% ROE.
- Analysts are generally positive—consensus rating is a “Moderate Buy” with an average price target of $505 while several firms have raised targets up to $600; the stock trades with a market cap of $21.09B and a P/E of 18.56.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Christopher Causey sold 1,000 shares of United Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $500.01, for a total value of $500,010.00. Following the completion of the transaction, the director owned 4,190 shares in the company, valued at approximately $2,095,041.90. This represents a 19.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Trading Down 1.4%
UTHR stock opened at $489.69 on Tuesday. The stock has a market capitalization of $21.09 billion, a P/E ratio of 18.56, a price-to-earnings-growth ratio of 4.77 and a beta of 0.84. The firm has a 50-day moving average price of $479.72 and a 200-day moving average price of $397.27. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analysts' expectations of $812.87 million. During the same period in the prior year, the company earned $6.39 EPS. The firm's quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Analysts Set New Price Targets
UTHR has been the topic of a number of research reports. UBS Group boosted their price objective on United Therapeutics from $580.00 to $600.00 and gave the stock a "buy" rating in a research report on Thursday, November 6th. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. Wells Fargo & Company upped their target price on United Therapeutics from $414.00 to $423.00 and gave the company an "equal weight" rating in a report on Thursday, October 30th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research note on Thursday, October 30th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $505.00.
Check Out Our Latest Analysis on UTHR
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 49 shares during the last quarter. Finally, Abich Financial Wealth Management LLC bought a new stake in United Therapeutics in the 3rd quarter valued at about $44,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
